EUCTR2019-004939-24-GB进行中（未招募）1 期
Phase I/II open-label study to assess the safety, tolerability and efficacy of a novel tissue engineered airway product, consisting of expanded autologous bone marrow (BM) derived Mesenchymal Stromal Cells (MSC) seeded on to a decellularised allogeneic patch of an airway scaffold in subjects with clinically significant bronchopleural fistula.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female subjects 18 years or older.
- •Documented diagnoses of BPF through imaging and bronchoscopic examination.
- •BPF which involves the tracheobronchial junction or proximal bronchus.
- •Subjects who have failed primary repair.
- •Subjects who have no evidence of any primary or recurrent cancer (not limited to the surgical site) at the time of pre-operative screening as evidenced by CT and/or targeted biopsy (except for controlled or controllable basal cell carcinoma.
- •Subjects who have signed and dated written informed consent to participate in the study.
- •Females of childbearing potential (i.e. not surgically sterilised or post-menopausal for at least 2 years) must have a negative serum or urine pregnancy test.
- •Male and female subjects of childbearing potential (i.e. not surgically sterilised or post-menopausal for at least 2 years) must use forms of highly effective methods of contraception, which are defined as hormonal methods of contraception (oral, injection or implant), barrier methods (condom or occlusive cap (diaphragm or cervical/vault caps)) with spermicidal foam/gel/cream/film/suppository, or true abstinence for 1 month following surgery.
- •Subjects who have produced viable cells from BMA.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who have received previous treatment with another Advanced Technology Medicinal Product (ATMP).
- •Subjects with ECOG performance status of 3 or 4.
- •Subjects deemed not suitable for surgery by the MDT.
- •Uncontrolled diabetes, defined as HbA1c levels above 7.0 %.
- •Any medical condition contraindicating the ability to tolerate general anaesthetic in the judgement of a consultant anaesthetist.
- •Subjects who have a severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
- •Subjects with clinically significant renal and liver impairment.
- •Subjects undergoing an immunosuppression regimen or suffering from a primary immunodeficiency syndrome.
- •Subjects with any known hypersensitivity to the culture and transport media compounds.
- •Subjects with current or recurrent disease that could affect the administration, the action or disposition of the investigational product, or clinical or laboratory assessments.
- •Subjects with clinically relevant or recent (within 2 years) history of substance abuse, including alcohol.
- •Subject who has participated in any other interventional clinical trial within previous 30 days of the start of this study.
- •Subjects with known presence of Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody.
- •Subject who, in the investigator’s judgement, is unlikely to complete all protocol required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
- •Subjects with any medical condition, that in the investigator’s judgement, is likely to interfere with assessment of safety or efficacy of study treatment.
- •Subject who is pregnant.
- •Subjects with cancer (except for controlled or controllable basal cell carcinoma).
研究者
相似试验
招募中
1 期
An Open-Label Exploratory Study of ABBV-CLS-7262 in Subjects with Vanishing White Matter DiseaseCTIS2023-505704-30-00Calico Life Sciences LLC14
进行中（未招募）
不适用
A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations - NDEUCTR2010-023412-13-ITOVARTIS FARMA54
进行中（未招募）
1 期
A clinical study evaluating the safety and efficacy of an investigational compound (MEK162) in adult patients with a specific type of advanced cutaneous malignant melanomalocally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mutationsMedDRA version: 20.0 Level: PT Classification code 10027480 Term: Metastatic malignant melanoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023412-13-DEArray BioPharma Inc.170
进行中（未招募）
1 期
A study to assess the safety and efficacy of MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mutationsEUCTR2010-023412-13-NLArray BioPharma Inc.170
已完成
2 期
A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mutationsskin cancerNL-OMON47322Array Biopharma31